Small Molecules

09 Feb 2007 DAIICHI SANKYO returns development rights of KAI-9803
09 Feb 2007 Results of Inhaled Treprostinil Controlled Pilot Studies Reported in the Journal of the American College Of Cardiology
09 Feb 2007 ISTA Pharmaceuticals Announces Positive Preliminary Xibrom(TM) Once-daily Formulation Clinical Results From U.S. Phase III Trials
09 Feb 2007 GlaxoSmithKline and Fabre-Kramer Pharmaceuticals enter global agreement for new treatment of major depressive disorder
09 Feb 2007 SRI International and Telik Announce Exclusive License for SRI to Develop Autoimmune and Inflammatory Disease Drug Candidate
09 Feb 2007 Pfizer's Sutent Receives FDA Approval to Include New First-Line Advanced Kidney Cancer Data in Label
09 Feb 2007 Gilead and Achillion Announce Positive Antiviral Activity of NS4A Antagonist in HCV, But Discontinue GS 9132 (ACH-806) Development
08 Feb 2007 FDA Grants Priority Review to Lovenox(R) (Enoxaparin Sodium Injection) Supplemental New Drug Application (sNDA) for Acute Heart Attack
08 Feb 2007 IntelGenx Technologies Corp. and Cary Pharmaceuticals Inc. Announce Enrollment of Phase I Pilot Study for QuitPak(R) (INT003/05)
08 Feb 2007 FDA Approves Orlistat for Over-the-Counter Use
08 Feb 2007 ViroPharma Receives Orphan Drug Designation for Maribavir for Cytomegalovirus Viremia and Disease Indication
08 Feb 2007 Bioenvision Files with EMeA for Label Extension of Evoltra
07 Feb 2007 Ilypsa, Inc. Completes Enrollment of Phase 2 Clinical Trial of ILY101 for Patients with Chronic Kidney Disease on Hemodialysis: Multi-Center Study Evaluating Safety and Efficacy of Ilypsa's Non-Absorbed Polymeric Drug for Hyperphosphatemia
07 Feb 2007 Spectrum Pharmaceuticals Announces Successful Completion of Patient Accrual in Its EOquin(R) Pilot Study, Prior to Initiating Phase 3 Studies in the U.S.
07 Feb 2007 Avigen Completes Safety, Tolerability and Pharmacokinetic Trial For AV411, a Potential First-in-Class Oral Treatment For Neuropathic Pain
07 Feb 2007 Trigen opens IND for the initiation of a Phase III programme for flovagatran (formerly TGN 255), its novel intravenous direct thrombin inhibitor (DTI)
06 Feb 2007 Amarin Announces Completion Of Two Phase III Trials With Miraxion In Huntington's Disease
06 Feb 2007 Biovitrum and Synphora Initiate Phase II Study of Psoriasis Treatment
06 Feb 2007 Arena Pharmaceuticals Completes Enrollment with 3,182 Patients in Lorcaserin Phase 3 BLOOM Trial for Obesity
06 Feb 2007 elbion and Wyeth Enter Collaboration to Develop New Treatments for Schizophrenia
06 Feb 2007 Antipodean Pharmaceuticals Initiates Phase 2 Trial in Hepatitis
06 Feb 2007 Cyclacel announces development plan for its seliciclib CDK inhibitor to treat nasopharyngeal cancer
05 Feb 2007 Phase III Trial of Progesterone for the Prevention of Preterm Birth in Women
03 Feb 2007 GlaxoSmithKline receives approvable letter for new indications for Arixtra(R) (fondaparinux sodium) injection
03 Feb 2007 Schering-Plough Cites Today's Anacor Agreement as Latest in Series of Deals

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up